Encouraging Activity in Poor-Risk Endometrial Cancer With HER2-Targeted Novel Drug

(MedPage Today) -- SAN JUAN, PUERTO RICO -- As many as 70% of patients with advanced/metastatic HER2-expressing endometrial cancer (EC) responded to an investigational antibody-drug conjugate (ADC), according to phase II data. Response to trastuzumab...
Source
MedPage Today
Opens original article in a new tab



